Events
-
-
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
ASCO 2026: Phase 3 PEAK study could usher in new second-line therapy for GIST
-
ASCO 2026: Personalised vaccine boosts immune activity against brain cancer
-
ASCO 2026: GLP-1s may reduce metastatic progression of certain obesity-related cancers
-
ASCO 2026: Yoga may help cancer survivors sleep better and reduce anxiety, fatigue
-
-
The Lancet Special Issue: Advancing racial and ethnic equity in science, medicine and global health
Timed to Human Rights Day on 10th December, The Lancet dedicates an issue to advancing racial and…
Novel nanoparticles deliver innovative cancer chemoimmunotherapy
University of Pittsburgh researchers have designed cancer-targeting nanoparticles that co-deliver a chemotherapy drug and a…
Experts warn of a European cancer epidemic in the next decade if weaknesses in cancer health systems and cancer research are not urgently addressed
The COVID-19 pandemic has exposed weaknesses in cancer health systems and in the cancer research…
Study finds treating precancerous growths in people with HIV reduces anal cancer by more than half
- p53 in liver cancer: The ultimate betrayal?
- Contrasting rates of survival for GI cancers in the Northern Territory
- ESMO: New phase III data show tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced oesophageal cancer in combination with chemotherapy
Improving cancer care in Botswana
It’s one of the scariest things a person could ever hear: “You have cancer.” Every single day, nearly 47,000 people…
JOIN THE ONCOLOGY NETWORK
If you would like even more free news articles, access to our exclusive HCP only content including the latest podcasts from The Oncology Podcast and our Industry Partner Podcasts (including links to all papers and show notes), along with all our other resources, head over to The Oncology Network and sign up - FREE forever for HCPs only.